|
목적 : To evaluate long-term visual outcome and investigate the prognostic factors after anti-vascular endothelial growth factor (VEGF) therapy for polypoidal choroidal vasculopathy (PCV)
방법 : Retrospective analysis were performed among 36 eyes (36 patients) with naive PCV were treated with intravitreal ranibizumab injections and completed at least 3-year follow-up. All clinical datas, including baseline characteristics, imaging data from fluorescein angiography, indocyanine green angiography, and optical coherence tomography, presence of recurrence, and best-corrected visual acuity (BCVA) were investigated.
결과 : During mean follow-up of 42.58±12.59 months, mean 11.45±7.81 injections were done. 24 eyes (66.7%) showed at least one recurrence. Mean BCVA was 0.68±0.43 logMAR (20/95 Snellen equivalent) at baseline, and 0.78±0.53 logMAR (20/120 Snellen equivalent) at 36 months (P=0.307). Mean BCVA was significantly improved at 1 month (P=0.018), and improvement maintained until 12 months (P=0.044), then deteriorated. Among baseline characteristics, greatest lesion diameter (B=0.219, P=0.001) and pigment epithelial detachment (B=0.362, P=0.025) were significantly correlated with long-term visual outcome.
결론 : Significant visual improvement by anti-VEGF therapy was maintained during first year of initial treatment, however, then vision was deteriorated during long-term follow-up. Smaller lesion size, absence of pigment epithelial detachment at baseline, and no recurrence during follow-up were significantly correlated with better long-term visual outcome.
|